%A Chen Ling, Guo Zengqing, Wang Xiaojie, Chen Yu, Yu Jiam %T Clinical observation of raltitrexed containing regimen for advanced colorectal cancer %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.08.006 %P 583-586 %V 44 %N 8 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10281.shtml} %8 2017-08-08 %X Objective To observe the clinical efficacy and adverse reactions of raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment. Methods A total of 42 patients with advanced colorectal cancer were treated with raltitrexed containing regimen. The objective response rate (ORR), disease control rate (DCR), median progressionfree survival (mPFS) and adverse reactions were evaluated. Results The ORR of the 42 patients was 16.67%, DCR was 80.96%, and mPFS was 4.90 months (95% CI:2.996.81 months). The most of adverse reactions were gradeⅠ-Ⅱ, including leucopenia (30.95%), thrombocytopenia (2.38%), anemia (40.48%), nausea and vomiting (2.38%), anorexia (4.76%), diarrhea (2.38%), transaminase elevation (47.62%) and fatigue (11.90%). Grade Ⅲ-Ⅳ transaminase elevation was found in only 4.76% of patients. Conclusion Raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment is effective and well tolerated, and further clinical application is recommended.